Please ensure Javascript is enabled for purposes of website accessibility

The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%

By Sean Williams - Oct 31, 2017 at 4:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stemline's lead drug dazzles in a pivotal-stage study, but investors should temper their expectations for the time being.

What happened

Shares of Stemline Therapeutics (STML), a small-cap clinical-stage biotechnology company with a focus on developing medicines to treat cancer, skyrocketed as much as 33% during Tuesday's trading session after reporting positive results from its pivotal midstage study involving lead drug SL-401.

So what

As announced before the opening bell, the company's interleukin-3 receptor (CD123) targeted therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) met the primary endpoint of its three-stage phase 2 study. More specifically, in the third of three stages, the results showed that seven of 13 (54%) first-line BPDCN patients demonstrated a complete response, with an overall response rate of 77% (10 of 13 patients). Of the seven patients with a complete response, six of them remained relapse-free at the five- to eight-month mark.

A biotech lab researcher reading a clipboard with a vial of blood in his left hand.

Image source: Getty Images.

Across all three stages, SL-401 led to a complete response (CR) rate of 60% for 45 patients (27 with CR) and an overall response rate of 82% (37 patients out of 45). When looking at all tested doses, the CR rate moved even higher to 69%, with an overall response rate of 88%.

Given these strong clinical results, along with feedback from the Food and Drug Administration (FDA), Stemline believes it's on track to begin submission of its Biologic License Application in the fourth quarter 2017 to first quarter 2018 time frame.

Also notable was commentary from Andrew Lane. M.D., Ph.D., Director of the BPDCN Center at the Dana-Farber Cancer Institute. Said Lane, "Given the presence of CD123 on additional aggressive hematological cancers, we are also exploring SL-401 in combination with other agents in clinical trials of high-risk MDS [myelodysplastic syndromes] and AML [acute myeloid leukemia]." The key here is that label expansion is a possibility after these strong results and the expression of CD123 on select malignancies. 

Now what

With no approved products, positive results from SL-401 were absolutely needed to provide a catalyst for Stemline Therapeutics. There are no currently approved therapies to treat BPDCN, which could give Stemline a clear path to success if the FDA approves it. However, it may not be a huge revenue generator right off the bat, with BPDCN accounting for less than 1% of all hematologic malignancies and less than 1% of primary cutaneous lymphomas.  

A hundred dollar bill on fire.

Image source: Getty Images.

Prospective investors should also be aware that as a clinical-stage drug developer with research and development expenses, cash burn is a genuine concern. Stemline ended the second quarter, reported in August, with $93.2 million in cash, cash equivalents, and investments, but could be on track to burn between $50 million and $60 million annually to run its studies and keep the lights on. For clinical-stage drug developers, issuing common stock and diluting existing shareholders tends to be par for the course when raising cash. 

To be clear, things are definitely looking up for Stemline. But with peak sales for BPDCN probably being modest at best, the real value here lies with the ability to potentially expand SL-401's label. Until we know more about the feasibility of this happening, it might be best to stick to the sidelines.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Stemline Therapeutics, Inc. Stock Quote
Stemline Therapeutics, Inc.
STML

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.